Table 1 Patient – and disease characteristics according to regular statin use among Swedish women diagnosed with breast cancer at age 40+ from July 1st, 2007 – December 31st, 2008. They were followed up until December 31st, 2012 for breast cancer related death, and, December 31st, 2013, for all-cause mortality
From: Statin use and breast cancer survival – a Swedish nationwide study
Characteristics | All | Non-regular statin use | Regular statin use | |
|---|---|---|---|---|
Age at breast cancer diagnosis | N | 8809 | 7717 | 1092 |
Median (min, max) | 64 (40,102) | 62 (40,102) | 70 (42,93) | |
Mean (SD) | 64 (13) | 63 (13) | 70 (9) | |
Breast cancer related death | ||||
No | 7717 (87.6%) | 6887 (89.2%) | 981 (89.8%) | |
Yes | 1092 (12.4%) | 830 (10.8%) | 111 (10.2%) | |
Diabetes mellitus pre-breast cancer diagnosis | ||||
No | 8264 (93.8%) | 7428 (96.3%) | 836 (76.6%) | |
Yes | 545 (6.2%) | 289 (3.7%) | 256 (23.4%) | |
All cause mortality | ||||
No | 7113 (80.7%) | 6250 (81%) | 863 (79%) | |
Yes | 1696 (19.3%) | 1467 (19%) | 229 (21%) | |
Breast cancer stage at diagnosis | ||||
Missing | 2310 (26.2%) | 2025 (26.2%) | 285 (26.1%) | |
0 | 1829 (20.8%) | 1596 (20.7%) | 233 (21.3%) | |
1 | 2378 (27%) | 2079 (26.9%) | 299 (27.4%) | |
2 | 1639 (18.6%) | 1426 (18.5%) | 213 (19.5%) | |
3 | 427 (4.8%) | 386 (5%) | 41 (3.8%) | |
4 | 226 (2.6%) | 205 (2.7%) | 21 (1.9%) | |
Type of statin beforea | ||||
No | 7435 (84.4%) | 7435 (96.3%) | 0 (0%) | |
Lipophilic | 1280 (14.5%) | 264 (3.4%) | 1016 (93%) | |
Hydrophilic | 94 (1.1%) | 18 (0.2%) | 76 (7%) | |
Type of statin used after diagnosisa | None | 6915 (78.6%) | 6876 (89.2%) | 39 (3.6%) |
Lipophilic | 1602 (18.2%) | 709 (9.2%) | 893 (81.9%) | |
Hydrophilic | 281 (3.2%) | 122 (1.6%) | 159 (14.6%) | |